ArticleTherapeutic advances in respiratory disease

Expression of concern: 'Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial'.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.